Stent Failure Symposium with Kevin Croce & Evan Shlofmitz

Dr. Evan Shlofmitz is an Interventional Cardiologist and the Director of Intravascular Imaging at St. Francis Hospital - The Heart Center in Roslyn, NY. He completed a fellowship in Interventional Cardiology at Georgetown University/MedStar Washington Hospital Center. He previously completed an Intravascular Imaging and Physiology fellowship at the Cardiovascular Research Foundation (CRF) and Columbia University Medical Center (CUMC), a Cardiovascular Disease fellowship at Northwell Health and served as Chief Resident for Internal Medicine at New York Presbyterian Queens. He serves on SCAI's IHD Council and is a co-director of Optimizing PCI (OPCI). His research interests have centered on intravascular imaging, the treatment of calcified coronary artery disease, in-stent restenosis and the optimization of stent implantation, with more than 100 publications in peer-reviewed journals.

Dr. Kevin J. Croce is an interventional cardiologist and the director of the Chronic Total Occlusion Complex Percutaneous Coronary Intervention Program at Brigham and Women’s Hospital (BWH). He is an assistant professor of medicine at Harvard Medical School (HMS) who also directs the BWH Translational Discovery Laboratory which is a centralized research facility that uses state-of-the-art technology to perform preclinical testing of promising therapies and medical devices. Dr. Croce received his medical and Ph.D. degrees from Tufts University School of Medicine. He completed an internal medicine residency, a cardiology fellowship and an interventional cardiology fellowship at BWH. Dr. Croce is board certified in internal medicine, cardiovascular disease and interventional cardiology. His clinical interests include advanced treatments for obstructive coronary artery disease (CAD), and optimization of antithrombotic and antiplatelet pharmacotherapy. The author of over 50 peer-reviewed publications, Dr. Croce’s research focuses on understanding the molecular pathobiology of atherothrombotic (CAD) and on identifying new targets for CAD treatment. His research has received support from the National Institutes of Health.